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Abstract | Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes 
by several years, by non-motor symptoms that include hyposmia, sleep disorders, depression 
and constipation. These non-motor features appear across the spectrum of patients with PD, 
including individuals with genetic causes of PD. The neuroanatomical and 
neuropharmacological bases of non-motor abnormalities in PD remain largely undefined. Here, 
we discuss recent advances that have helped establish the presence, severity and effect on the 
quality of life of non-motor symptoms in PD, and the neuroanatomical and 
neuropharmacological mechanisms involved. We also discuss the potential for the non-motor 
features to define a prodrome that may enable the early diagnosis of PD.  
  
Parkinson disease (PD) is a progressive neurodegenerative disorder that involves multiple 
neurotransmitter pathways within the brain and autonomic nervous system that in turn are 
associated with a range of clinical features (TABLE 1). The diagnosis of PD is currently 
dependent on the presence of motor deficits including bradykinesia, rigidity and tremor, usually 
manifesting unilaterally or at least asymmetrically1. The motor features are predominantly a 
consequence of the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), 
and the symptomatic therapy used in PD currently focuses on dopamine replacement 
strategies. Advancing disease and increased doses of levodopa result in the development of 
motor complications that are characterised by wearing off periods and off periods, during which 
bradykinesia and rigidity reappear, an absence of on periods and the development of 
involuntary dyskinesias2. 
Although the diagnosis of PD relies on the clinical effects of dopamine deficiency, this 
disease is associated with other neurotransmitter deficits that are recognized to cause various 
motor and non-motor symptoms and signs. Some of these symptoms and signs — for example. 
hyposmia, rapid eye movement (REM) sleep behaviour disorder (RBD), depression and 
constipation — can precede the symptoms related to dopamine deficiency by several years3. 
Alternatively, these and other non-motor problems may arise later in the disease (FIG. 1). 
Global cognitive decline, in particular executive dysfunction and problems with working memory, 
has been also described in people at risk of developing PD 4.  
 Although subtle cognitive deficits may be present at the diagnosis of PD, these become 
more significant in the later years of the disease, and they are often present in people with PD 
aged over 70 years old regardless of the age of disease onset5. Indeed, with the progression of 
neurodegeneration and advancing disease, non-motor problems such as cognitive impairment, 
autonomic dysfunction and sleep disorders come to dominate the clinical picture and are the 
main determinants of quality of life and institutionalisation (FIG. 2)6. Indeed recent evidence 
suggests that PD may have several endophenotypes, and some of these endopheotypes are 
dominated by non-motor symptoms7. 
Two of the major therapeutic challenges for PD are the development of disease-
modifying treatments to slow or prevent the progression of neurodegeneration, and the 
development of effective symptomatic interventions for non-motor features. This Review will 
summarise the spectrum of non-motor problems in PD, addressing the pathological, 
pharmacological and clinical aspects of each, the model systems developed to study them, and 
the prospects of using non-motor features to define a pre-diagnostic prodrome of PD. In 
discussing the potential modelling of non-motor features of PD, we recognise the limitations of 
existing toxin and genetic animal models in recapitulating the clinical and pathological 
characteristics of the disease, as well as its progressive nature — a feature specifically lacking 
in the toxin models. It is also important to distinguish animal models based on toxins, such as 
rotenone or 6-hydroxydopamine (6-OHDA), which do not act through mechanisms that reflect 
the complex pathogenic processes underlying PD, from those based on genetic forms of PD, 
most frequently α-synuclein transgenic mice. The lessons from these mice are limited by the 
lack of comprehensive investigation of non-motor symptoms in any one study or any one non-
motor symptom with different models, including different species and strains. No model type, 
toxin or genetic, has shown consistency in the evaluation of any specific non-motor feature. 
Furthermore, we also accept that the presence of motor symptoms may interfere with the ability 
to evaluate of non-motor abnormalities such as anxiety, depression and cognition. Despite 
these caveats, the animal models described can provide some insight into the pathology and 
pharmacology of non-motor dysfunction in PD. The pharmacological basis of the non-motor 
features of PD is of relevance to the development of future therapies. Currently, dopaminergic 
treatments are the most widely used therapies, but they have no impact on those aspects of the 
disease that are related to other neurotransmitter deficits. This is reflected in the limited 
therapies available for non-motor deficits8. 
 
[H1] Sensory features 
 
Sensory symptoms, and pain in particular, are common non-motor features of PD. Indeed, 
virtually all patients with PD experience at least one sensory symptom as part of their prodrome, 
and such symptoms increase in prevalence and severity with the progression of the disease.  
 
[H3] Olfactory deficits. Hyposmia or anosmia develops in more than 90% of patients with PD, 
is usually bilateral and may precede the onset of the dopamine deficiency-related motor 
features9. Although hyposmia is not often reported by patients, the presence or progression of 
hyposmia could represent a biomarker for early pre-motor PD, particularly if it is combined with 
other early clinical, imaging and/or biochemical markers, such as reduced noradrenergic 
denervation of cardiac tissue and cognitive dysfunction10-14. The development of hyposmia and 
RBD (see below) may reflect the evolving distribution and spread of Lewy bodies in PD from the 
lower medulla, as described by Braak and colleagues (FIG. 3)15. However, the presence of 
olfactory dysfunction in later stages of PD may also be linked to cholinergic denervation and the 
onset of cognitive deficits and dementia16,17.  
Alterations in olfaction in PD seemingly owe to changes in central olfactory processing, 
as biopsy samples of the olfactory epithelium from individuals with the disease are normal18. 
Indeed, MRI studies revealed that, compared with healthy controls, individuals with PD showed 
varying degrees of decreased volume of and sulcus depth in the olfactory bulb19. Moreover, 
Lewy bodies and Lewy neurites, as detected by α-synuclein immunoreactivity, were found in the 
olfactory bulb, the olfactory cortex and other brain regions related to olfaction (including the 
amygdala) in PD and in incidental Lewy body disease (ILBD) but rarely in healthy controls20,21,. 
Individuals with PD also showed a loss of mitral cells and substance P-containing cells in the 
olfactory bulb, and a reduction in the level of calcium binding protein in this region, but 
dopaminergic- or somatostatin-containing cells are rarely affected in either the olfactory bulb or 
associated nuclei22. Patients with PD also showed an increase in periglomerular dopaminergic 
neurons, although this finding was not specific to PD as it also occurred in Alzheimer disease 
(AD) and in frontotemporal dementia. The failure of olfactory deficits to respond to dopaminergic 
medications probably reflects the lack of involvement of dopaminergic systems in the olfactory 
defects23.  
Some evidence exists for olfactory deficits in rodent models of PD but this evidence has 
proved controversial. Mice and rats receiving intranasal or intra-peritoneal 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) to model PD exhibited impaired olfaction and reductions in 
the levels of dopamine and noradrenaline in the olfactory bulb24,25. However, impaired olfaction 
following intranasal administration of MPTP may simply reflect damage to the olfactory 
epithelium26. No evidence exists to suggest that administration of MPTP causes olfactory 
changes in primates. 
Mice overexpressing human wild-type α-synuclein, a transgenic model of PD, have 
olfactory deficits: they show progressive losses in the abilities to detect and discriminate odours, 
which is associated with α-synuclein accumulation in the olfactory bulb, although no evidence 
exists for dopaminergic cell loss at least in the substantia nigra27-29. Mice expressing α-
synuclein–green fluorescent protein (GFP) also display olfactory dysfunction as well as 
progressive motor impairment and the accumulation of α-synuclein-GFP in the olfactory bulb 
30,31. These mice do not show increased sensitivity to olfactory neuronal loss following the 
administration of paraquat32. Furthermore, mice carrying the human α-synuclein A53T mutation 
show progressive α-synuclein accumulation in the olfactory bulb, marked loss of glutamatergic 
and calcium binding protein immunoreactivity, but no change in the number of dopaminergic 
cells33. However, in this particular study, no assessment of olfaction was made.  
Why rodents express some abnormalities in olfactory function and pathology in these 
toxin and genetic models is not clear, but these deficits may reflect the greater CNS 
representation of olfaction in these animals than in primates. Interestingly, the temporal 
expression pattern of α-synuclein modulates olfactory neurogenesis in transgenic mice34. 
Therefore, overall, these findings are consistent with the concept that olfactory changes occur 
early in the course of PD and can precede the onset of motor deficits that owe to dopaminergic 
cell loss, and that they may be linked to α-synuclein-mediated pathology and to altered 
neurogenesis. Olfactory function has emerged as an important component of the PD clinical 
prodrome but our ability to model its pathological basis has limited our understanding of its 
relationship to the progression of the disease. 
  
[H3] Visual disturbances. Visual disturbances in general are relatively common in PD with 
some studies reporting that up to 78% of patients are affected by such disturbances35,36, 
although another study reported that visual symptoms occurred in 22% of people with PD 
versus 4% of age-matched controls37. The incidence of visual hallucinations and diplopia 
(double vision) in PD increases with disease progression38. Impaired acuity does not improve 
with dopaminergic therapy, and indeed visual hallucinations may worsen, particularly with 
dopamine agonist treatment39. Some of the visual disturbances in PD, particularly 
hallucinations, have been linked to the presence of Lewy bodies in the occipital lobe and in 
retinal neurons, and to the loss of dopaminergic amacrine cells and the regulatory role of D1 
dopamine receptors (D1Rs) and D2Rs in the eye40. Altered visual fields occur in primates 
following administration of the dopaminergic toxin MPTP and intra-ocular injection of the 
catecholaminergic toxin 6-OHDA, again suggesting some direct involvement of altered 
dopaminergic function in the eye41,42. There is also some evidence to suggest that thinning of 
the retinal nerve fibre layer occurs in patients with PD, as identified by ocular coherence 
tomography, but this finding is disputed43,44. Mutations in glucocerebrosidase (GBA) are 
numerically the most important risk factor for PD45 and retinal thinning has been described in 
carriers of these mutations with and without PD46.This finding suggests that retinal thinning may 
be used as part of a PD risk calculator for GBA mutation carriers. In PD patients with normal 
vision, electrical activity of the fovea, which is responsible for central acuity, is decreased and 
retinal thinning is present47, which may reflect decreased innervation around the fovea and 
reduced retinal dopamine concentrations in these individuals.  
Hallucinations, previously thought to be typical drug-related adverse effects in advancing 
PD, have now been reported to occur even in untreated PD in the prodormal phase48. The 
development of visual hallucinations is associated with cognitive impairment and dementia in 
PD and such hallucinations may be a good predictor of cognitive decline in later disease49.  
Visual hallucinations in PD have been linked with perceptual, executive and sleep dysfunction 
and probably reflects the distribution of Lewy body pathology22,50. Treatment with dopaminergic 
therapies, especially dopamine agonists, is associated with an increased risk of visual 
hallucinations, implying that dopaminergic signalling is involved in their generation39.  
 
[H3] Pain and somatosensory disturbances. Changes in sensory function and onset of pain 
are a common feature of PD affecting 30–85% of the patient population51,53, and remain under-
reported 51,54-60. Pain in PD has various causes6,54-61. Several methods have been proposed to 
classify the complex pain syndrome of PD, and they mainly cover, or have been applied to two 
broad categories of pain, namely nociceptive and neuropathic pain51,55 . Pain also fluctuates with 
the motor state of the patient, often worsening during the off state (termed ‘off related pain’), 
whereas in some patients a central variant of pain is evident55-57, 62,63.  
A variety of causes of sensory-related symptoms in PD have been identified, which can 
be largely divided according to whether they have a musculo-skeletal origin (for example, 
causes that result in stiffness, dystonia or muscle cramps) or they have a central origin and are 
primarily related to the neurodegenerative process in PD6. Other sensory changes occur in PD, 
including peripheral paraesthesia, burning sensation and the so called ‘burning mouth 
syndrome’, all of which can be recognised using the Chaudhuri–Schapira classification of pain 
in PD6. 
The basal ganglia sustain sensory function through the modulation and integration of 
information from the substantia nigra, cortex, thalamus and many other nuclei. In PD, loss of 
dopaminergic input to the basal ganglia alters sensory perception and changes pain 
thresholds64,65. However, dopamine can also modulate pain in regions outside of the basal 
ganglia, including the spinal cord, thalamus, periaqueductal grey and cingulate cortex66. 
Evidence exists indicating that dopaminergic function may modulate sensory perception: for 
instance, pain occurs more frequently in patients during off periods and pain thresholds are 
raised by dopaminergic medication67. However, dopaminergic medication does not eliminate 
pain in PD and therefore additional non-dopaminergic mechanisms must underlie this symptom. 
The ascending and descending pathways are involved in pain: for example, the spino-thalamic 
tract sends collaterals to the locus coeruleus, raphe nuclei, amygdala and thalamus, and these 
areas receive inputs from higher centres to control the sensitivity and excitability of the 
somatosensory system68-70. The serotonergic raphe nuclei and the noradrenergic locus 
coeruleus are both affected by pathological change in PD and both play a role in ‘gain setting’ 
for pain control71.The raphe nuclei send descending fibres to the dorsal horn of the spinal cord 
that modulate pain processing72 and the nociceptive neurones in lamina I of the dorsal horn 
show α-synuclein immunoreactive inclusions in PD73. Peripheral de-afferentation may also occur 
in PD, which may affect nociceptive input to the spinal cord74. Thus multiple neurotransmitter 
pathways subserve the symptom of pain in PD, and it is challenging therefore to provide specific 
pain-relieving treatments. 
 In the clinical arena, classification of the type of pain in PD is essential for correct 
diagnosis and treatment. There are both dopaminergic and non-dopaminergic pain pathways, 
as well as neuropathic and nociceptive pain. Clinical classification is aided by the recent 
validation and description of the Kings Parkinson Pain Scale (KPPS), which is based on the 
Chaudhuri–Schapira classification of pain and classifies pain in PD to musculoskeletal, 
fluctuation related, central, nocturnal orofacial and peripheral pain75. The KPPS has aided the 
reporting of the first ever randomised placebo controlled trial of an opiate (oxycodone combined 
with naloxone) to treat pain in PD (the PANDA study (NCT014391000))76 and of a randomized 
trial with the rotigotine transdermal patch (the DOLORES study (NCT01744496)77.  
The treatment of pain in PD is first directed to the relief of symptoms related to off 
periods and involves administration of dopaminergic medications; such agents may be 
combined with analgesics or pain-modulating drugs as required52. Painful dystonia may be 
relieved with botulinum injections in selected patients who do not respond to changes in their 
dopaminergic therapy78.  Current evidence, therefore, allows clinical classification of pain using 
the KPPS and the initiation of  individualised therapies. Fluctuation-related pain could be 
managed by strategies that use continuous drug delivery such as the rotigotine patch or other 
drugs given by infusion while non-dopaminergic medication-responsive pain may require use of 
opiate or other analgesia, as suggested by the PANDA study79.  
 
[H1] Neuropsychiatric features 
 
Neuropsychiatric features such as anxiety and depression occur in PD from the prodromal pre-
motor phase to the late stages of the disease and they fluctuate with the motor state; anxiety in 
particular is dominant during off periods. Overlap between anxiety and depression is also 
common, the anxious depressed phenotype and recognition is important for effective 
management.  
 
[H3] Anxiety. Anxiety affects up to 60% of patients with PD and encompasses generalized 
anxiety (apprehension, fear and worry), panic attacks and social phobias, and it is commonly 
but not always accompanied by depression80,81. Anxiety is seen more commonly in females, 
patients with disease onset at a young age and patients with advanced disease82. Levels of 
anxiety increase with motor fluctuations, which are associated with periods of low dopamine 
levels, and with the onset of off periods or freezing83. Dopaminergic therapy and deep brain 
stimulation improve symptoms of depression, which may be secondary to improved motor 
function and could also indicate a dopaminergic component to anxiety81,84. Anxiety, often in 
association with depression, can occur prior to the onset of motor signs of PD, suggesting this 
symptom may be related to pathology outside the nigrostriatum85. 
Positron emission tomography (PET) imaging using the catecholaminergic binding ligand 
11C-RTI-32 has revealed that in PD patients with depression and anxiety, but not PD patients 
without depression, there was a decrease in the binding of this ligand, and that the level of 
binding was inversely correlated with the severity of anxiety but not depression86. This suggests 
that anxiety has a separate neurochemical basis to depression in PD patients with both. Clinical 
studies have also suggested the existence of several phenotypic variants of anxiety and 
depression in individuals with PD, ranging from those who exhibit both anxiety and depression 
to those with anxiety- or depression-alone subtypes82.  
Bilateral 6-OHDA lesioning of the nigro-striatal pathway in rats leads to increased 
anxiety-like behaviour in the elevated plus maze and is associated with reductions in dopamine, 
noradrenaline and 5-HT levels87 
 in this task88. In genetic models of PD, parkin-null mice and vesicular monoamine 
transporter 2 (VMAT2)-deficient mice at 6 months show signs of anxiety-like behaviour in the 
elevated plus maze89,90. Overexpression of wild-type α-synuclein in mice decreases anxiety-like 
behaviour in the elevated plus maze and the light–dark box paradigm, but this change in 
behaviour may reflect hyperactivity, as increased anxiety-like behaviour is observed in fear-
conditioning tests in these mice28. In rats, subcutaneous infusion of paraquat and orbilateral 
delivery of α-synuclein into substantia nigra using a viral vector induced anxiety-like behaviour91. 
However, despite the behavioural changes observed in these models, little evidence exists to 
explain the pathological or biochemical basis for the expression of anxiety in people with PD. 
 
[H3] Depression. Depression is common in patients with PD and considered clinically 
significant in 35% of the patient population92. In comparison with depression observed in people 
without PD, PD-related depression is generally milder, although it more frequently involves 
apathy and anhedonia.  
Depression in PD may predate the onset of motor symptoms93. It has been correlated 
with disease duration, the severity of motor symptoms, the occurrence of motor complications or 
fluctuations and the dosage of dopaminergic medication94. Moreover, cognitive decline and 
dementia, psychotic episodes, anxiety, sleep disturbance and autonomic symptoms have all 
been linked to an increased risk of depression in PD95. Thus, depression in PD is a complex 
phenomenon that may be a consequence of PD pathology, a reaction to the PD-associated 
disability, a separate phenomenon, or a combination of all three96. This possible complexity in 
the causation of PD probably accounts for the improvement of depression in only a proportion of 
PD patients with dopaminergic therapy. 
As in endogenous depression, depression in PD is related to changes in dopaminergic, 
noradrenergic and serotonergic systems86. In addition, the loss of cortical cholinergic neurons 
may contribute to depression in PD. However, as the loss of this neuronal population also 
underlies the onset of dementia, it may be difficult to discriminate the clinical effects of such 
neurodegeneration in the early phase of dementia97.  
Dopamine transporter availability in the striatum and limbic brain regions (the anterior 
cingulate cortex, amygdala and ventral striatum) is reduced in PD patients with depression 
compared with individuals with PD but not depression86,98. Furthermore, MRI has revealed that 
people with PD-related depression also show a loss of white matter loss in cortico-limbic 
regions, which is a major site for the dopaminergic regulation of mood, motivation and reward99.  
Serotonergic function is linked to depression in the general population but there is mixed 
evidence for its involvement in depression in PD86. Degeneration of neurons in the raphe nuclei 
occurs in PD with a corresponding decrease in forebrain 5-HT innervation, as shown in imaging 
studies and post-mortem investigations. However, although there may be changes in 5-HT 
availability in the raphe nuclei and hypo-echogenicity on trans-cranial sonography, other 
functional imaging studies using PET failed to show any differences between the serotonergic 
systems in cases of PD with and without depression100. Cell loss in the dorsal raphe nuclei did 
not differ between PD patients with and without depression99. In addition, mixed evidence exists 
regarding whether selective 5-HT reuptake inhibitors are effective treatments for depression in 
PD101. 
By contrast, there is stronger evidence for a change in noradrenergic function in 
depression in PD. Imaging studies have showed that PD patients with depression exhibit 
reductions in dopaminergic and noradrenergic innervation in the locus ceruleus, thalamus and 
limbic brain regions and increases in neuronal loss and gliosis in the locus ceruleus82, 102, 103. 
Interestingly, anti-depressant drugs that affect noradrenaline reuptake, namely tricyclic 
antidepressants like nortriptyline, may be more effective than other drugs in the treatment of 
PD-related depression104. 
Increased depression-like behaviour has been observed using the forced swim and 
sucrose preference tests in 6-OHDA-lesioned and MPTP-treated rodents, and rotenone infusion 
into substantia nigra in rats was associated with altered dopaminergic and serotoninergic 
transmission89,105. VMAT2-deficient mice that showed a progressive depressive-like syndrome in 
the forced swim test also exhibited alterations in forebrain dopamine, noradrenaline and 5-HT 
levels91.  
 
[H3] Apathy and fatigue. Apathy occurs in 60% of individuals with PD and it is increasingly 
recognised as a distinct non-motor component of the disease106. Apathy may co-exist with 
depression and dementia in PD but can also occur independently of both, and has been 
reported in cases of early-stage PD107,108. A report showed that among individuals with PD, 
those with apathy had reductions in grey matter density in the cingulate gyrus and inferior frontal 
gyrus109, although another investigation did not find any fronto-temporal atrophy in PD patients 
with apathy110. Alternatively, apathy in PD may involve ventral striatal and limbic brain areas, as 
a group of PD patients developed apathy after deep brain stimulation in the subthalamic 
nucleus. Apathy in PD patients has also been associated with atrophy of the left nucleus 
accumbens111. Finally, subtypes of apathy have been described and defined according to 
whether they are. underpinned by a dopaminergic or a cholinergic dysfunction112. 
MPTP-treated non-human primates also display apathetic behaviour. In such primates, 
apathetic behaviour correlated more strongly with loss of dopaminergic cells in the ventral 
tegmental area, which projects to the nucleus accumbens, and with expression levels of the 
dopamine transporter in the nucleus accumbens, than with the degree of motor impairment. In 
PD patients, apathy may improve with dopaminergic medication but there has been little 
controlled evaluation of drug treatment105,106,  although apathy occurring after DBS responded to 
treatment with a dopamine agonist (ropinirole)113 
Few clinical trials have focused on PD populations with apathy (as defined by the use of 
validated scales). One, 12-week placebo-controlled, double-blinded randomised study of 
piribedil, a dopamine agoinst, found that treatment with this agent at a dosage of up to 
300mg/day led to a 34.6% reduction in apathy scores at 12 weeks (by contrast placebo reduced 
such scores by 3.2%)114. In addition, the role of the cholinergic system in apathy was translated 
to a 6-month multicenter, parallel, double blind, placebo-controlled randomised controlled trial of 
rivastigmine (administered via a transdermal patch at 9.5 mg/day; CT00767091), which reported 
that this treatment led to a marked improvement in apathy115. 
Fatigue in PD is characterised by a lack of energy, exhaustion and tiredness, is distinct 
from apathy, and affects approximately 50% of the patient population52. Fatigue can be a 
consequence of motor dysfunction in PD or be directly related to the neuropathology, as it can 
be observed in treated patients with good motor function. The presence and severity of fatigue 
is not associated with the duration of PD or the severity of motor symptoms and it can appear 
before motor signs are recognised. In some patients, but not all, fatigue may be associated with 
the presence of depression, nocturnal sleep disturbance and autonomic symptoms. There is no 
association between the presence of fatigue and the type, duration or dosage of anti-
parkinsonian medication used for treatment, although it improves with a reduction in off 
periods116. Basal ganglia dysfunction has been implicated in fatigue because of their 
connections to the limbic system117. However, no differences in dopamine transporter 
expression in the striatum have been found between PD patients with and without fatigue118. By 
contrast, patients with PD and fatigue showed reduced 5-HT transporter levels in the caudate 
nucleus, putamen, ventral striatum, thalamus, cingulate and amygdala compared with PD 
patients without fatigue119.  
 
[H3] Cognitive deficits and dementia. Cognitive decline and dementia are usually considered 
to be a component of late-stage PD or as a consequence of senescence; up to 83% of patients 
with PD may be affected by some level of cognitive dysfunction120. Individuals with a 
predominantly bradykinetic-rigid form of PD are more at risk of subsequently developing 
dementia than people who have the tremor-dominant form of the disease121. Late-onset 
dementia is characterised by visual spatial constructional deficits and recognition, semantic and 
episodic memory loss. These deficits do not have a basal ganglia origin but are associated with 
Lewy bodies in posterior cortical regions, notably the parietal and temporal lobes. The density of 
cortical Lewy bodies and Lewy neurites seems to correlate with the severity of dementia122. 
Distinguishing individuals with PD with dementia from those patients with dementia with Lewy 
bodies (DLB) or AD is sometimes difficult because both clinical and pathological changes can 
overlap. Indeed, tau-, amyloid- and α-synuclein-positive inclusions are present in all three 
conditions123.  
Dementia in PD is accompanied by a substantial reduction in cortical cholinergic 
markers, explaining the limited clinical response to cholinesterase inhibitors that can be seen in 
some patients124. By contrast, dopaminergic drugs have little effect and can worsen psychosis 
and hallucinations associated with the dementia. However, the continual degeneration of 
brainstem nuclei as PD progresses may also be a contributory factor to cognitive decline in 
older patients. A greater loss of the dopamine transporter and dopaminergic terminals in the 
striatum and inferior frontal gyrus has been observed in PD with dementia than in PD without 
dementia125,126. There is also some evidence for a more severe loss of noradrenergic input from 
the locus coeruleus to cortical regions in cases of PD with dementia than in cases of PD but no 
dementia127.   
Mild, usually clinically asymptomatic cognitive impairment is also a common but under-
recognised component of early PD, and the main feature of this early cognitive syndrome is 
impairment in executive function128.  Early cognitive impairment is considered to be a fronto-
striatal disorder that is dopamine dependent and, for which, some components (for example, 
executive function) may be improved by dopaminergic drugs129. Other features such as 
recognition memory and cognitive flexibility do not respond to such drugs, suggesting the 
involvement of different neurotransmitters128. Early cognitive impairment may also be influenced 
by polymorphisms affecting dopaminergic function. Polymorphisms determining high enzyme 
activity in the gene encoding catechol-O-methyl transferase (COMT) are associated with less 
impairment and therefore suggest that early cognitive dysfunction is attributable to a state of 
relative hyperdopaminergic activity in the dorsolateral prefrontal cortex compared with that in the 
striatum.130 Importantly, cortical dopamine levels rise in early PD to compensate for the loss of 
dopamine that occurs in the striatum131, and this compensation may adversely affect cognition, 
as there is an inverted U-shaped relationship between the dopamine concentration and 
cognition132. However, no change occurs in the density of D1Rs, which represent the dominant 
subtype of dopamine receptor that is present in cortical areas133. Too little or too much 
dopamine may therefore be detrimental and this may explain why cognition fluctuates with 
disease progression and with dopaminergic medication134.   
Cognitive deficits in PD have been extensively studied in rodents using lesions of the 
nigro-striatal pathway induced by 6-OHDA or MPTP28,135. A variety of tests on such rodents 
have shown that they exhibit impairments in cognition, but these deficits reflect the 
consequences of acute or severe lesions, rather than the progressive pathology of PD, and so 
will not necessarily reflect the cognitive decline and dementia that are observed in humans with 
this disease. These observations of cognitive dysfunction are also limited by many tests being 
dependent on motor function and the consequent effect of an induced parkisonian state on test 
performance. Changes in cognition have also been reported in ageing mice that overexpressed 
wild-type or mutant α-synuclein136. In a conditional model, mice expressing high levels of human 
wild-type α-synuclein in midbrain and forebrain regions showed cognitive impairment and 
developed mild nigral and hippocampal neuropathology137. However, in a different study, mice 
expressing human wild-type α-synuclein and showing extensive cognitive deficits had no 
pathology in the hippocampus but exhibited cholinergic deficits in the cortex138. The cholinergic 
deficit may reflect early changes in brain regions outside the basal ganglia as this deficit 
preceded striatal dopamine loss. Early cognitive decline is also seen in MPTP-treated non-
human primates, in which chronic low dose treatment leads to alterations in executive function 
and attention139. These abnormalities are the same as those seen in patients in the early stages 
of PD, so this model appears promising for the testing of new drug entities for cognitive 
dysfunction — for example, D1R agonists and α-7 subunit-containing nicotinic acetylcholine 
receptor agonists140,141, or other drugs that may target a specific pharmacological defect. 
However, MPTP is not associated with α-synuclein pathology and so could not be used to test 
drugs designed to target α-synuclein pathology and its role in cognitive decline. 
 
[H3] Psychosis. Psychosis in PD typically occurs later in the course of the illness and common 
symptoms include visual hallucinations and delusions, which are present in up to 40% of cases 
of PD100,142-144. Dopaminergic therapy with levodopa and dopamine agonists can induce 
psychosis and such therapy was originally thought to explain its occurrence in PD.  
Abnormal visual processing, sleep dysfunction and pathological and neurochemical 
changes have all been linked to psychosis in PD144. Although MRI studies have shown little 
structural change in cortical regions in PD patients with psychosis compared with PD patients 
without psychosis, they have shown alterations in the processing of visual stimuli145. Decreases 
in retinal dopamine concentrations (see above) may also contribute to changes in visual 
perception and processing in PD146. During sleep, vivid dreams, nightmares and night terrors 
occur more frequently in those patients with psychoses and these phenomena may have similar 
underlying mechanisms to daytime hallucinations147, 148.  
Classical anti-psychotics such as dopamine antagonists and atypical 5-HT-based 
antipsychotics are used to control symptoms of psychosis, suggesting that dopamine and 5-HT 
may have a role in psychosis in PD. Among individuals with PD, forebrain 5-HT levels are lower 
in those with psychosis than in those without psychosis149. Acetylcholine may also contribute to 
psychosis, as cortical dennervation in later stages of PD is related to susceptibility to psychosis 
in PD as well as in AD150. Anticholinergic drug use can also cause the emergence of psychosis 
in PD possibly by further impairing already diminished cortical cholinergic transmission151. 
Hallucinations in PD are associated with the presence of Lewy bodies in the amygdala and the 
frontal, temporal, parietal and visual cortices, suggesting that pathological changes in PD may 
directly contribute to hallucinations152. 
Few studies of experimental models of PD have investigated psychosis. In one study, a 
rating scale for psychosis-like behaviour in response to dopaminergic drugs was reported in 
MPTP-treated nonhuman primates153-155. Whether the behavioural changes observed reflected 
psychotic processes is a matter of conjecture but the behaviours rated do respond to typical and 
atypical antipsychotic drug treatment.  
 
[H1] Sleep disorders 
Disturbances in sleep and wakefulness affect most of the PD patient population and their 
prevalence increases with the duration of disease156. Such disturbances take a variety of forms. 
Daytime somnolence and ‘sleep attacks’ can be differentiated from nocturnal sleep 
disturbances. Night time sleep disorders include insomnia, which can be disease or drug-related 
and involve sleep fragmentation and frequent, prolonged awakening, RBD, periodic limb 
movements, restless leg syndrome and akathisia157. The return of motor symptoms when drug 
effects wear off during the night, dyskinesia and/or dystonia related to drug action, nightmares, 
hallucinations and nocturia can all exacerbate sleep disturbances158.  
Dopamine, noradrenaline and 5-HT are involved in the control of sleep and all of these 
transmitter systems are affected in PD159. Dopaminergic cells in the periaqueductal grey are 
activated during wakefulness in the rat and lesions of this region increase sleep periods160. 
Excessive day time sleepiness and sleep attacks may be worsened by some dopamine receptor 
agonist drugs, and sleep disorders, such as narcolepsy, may be treated using dopaminergic 
medications, suggesting a link to altered dopaminergic neuronal function161.  
Dopaminergic neurons in the ventral tegmental area–substantia nigra receive inputs 
from hypothalamic hypocretin (orexin) neurons and form loops controlling arousal and 
wakefulness ascending through the thalamus and cortex and descending via the 
pedunculopontine nucleus and the reticular formation.162 Hypocretin is almost undetectable in 
both PD and non-PD patients with narcolepsy and decreases in the number of hypocretin 
neurons and in hypocretin levels in the cerebrospinal fluid and frontal cortex have been reported 
in PD163,164. Similarly, restless leg syndrome, periodic limb movements and akathisia appear to 
have a dopaminergic component given that levodopa and dopamine receptor agonists can 
improve these symptoms81,165. However, what is not clear is whether the dopaminergic 
components are central, peripheral or both. 
Insomnia in patients with PD also may be related to disease pathology, but also to too 
little or too much dopaminergic therapy. MPTP-treated mice and monkeys have changes in 
sleep patterns and in REM sleep that can be manipulated by dopaminergic drugs, notably D1R 
agonists166-169. By contrast, RBD appears to have a different origin as it can occur early in the 
course of the disease process, long before the onset of obvious motor signs170. 
Braak and colleagues have observed the distribution of Lewy bodies in non-PD post-
mortem brains and suggested that early pathology begins in the lower brain stem and ascends 
to involve the mid-brain and then the cortex15. The olfactory nucleus may also be involved at the 
time of medullary Lewy body pathology, although neurodegeneration begins in the substantia 
nigra. Wild-type α-synuclein overexpression leading to brain stem and cortical accumulation is 
associated with sleep disturbances in mice171. The concept of early brain stem involvement has 
been used to explain the early non-motor features of hyposmia and sleep disturbance in 
patients with PD172,173. 
 
[H1] Autonomic dysfunction 
Autonomic dysfunction in PD is common and may precede motor features, but it becomes more 
prevalent as the disease progresses. Autonomic problems encompass bladder, bowel and 
sexual dysfunction, as well as cardiovascular complications such as postural hypotension. 
 
[H3] Bladder dysfunction. Urinary dysfunction in PD includes nocturia, and increased 
frequency and urgency of micturition, which are associated with detrusor hyper-reflexia. 
Micturition regulation is dependent on the autonomic arc of the sacral spinal cord segments, but 
it is tonically facilitated by the pontine micturition centre; the storage function is facilitated by the 
hypothalamus, cerebellum, frontal cortex and basal ganglia174-176. Bladder hyper-reflexia in PD is 
thought to be related to loss of the basal ganglia’s inhibitory role. Reduced dopaminergic 
function and globus pallidus activity can be seen in imaging studies in people with PD and 
bladder dysfunction compared with PD patients with normal bladder function177,178. More 
specifically, the D1R-mediated output from the basal ganglia has an inhibitory effect on 
micturition but the D2R mediated output is facilitatory179. Striatal dopamine transporter loss 
correlates with the severity of bladder symptoms, and caudate neurodegeneration with 
transporter loss may be a greater predictor for bladder symptoms than putaminal loss68. Bladder 
symptoms may improve in a minority of PD patients with dopaminergic therapy180.  The 
dopaminergic effects are complex with postulated roles for D1Rs and D2Rs, dopamine auto-
receptors and post-synaptic sites and central and peripheral dopamine receptor stimulation181. 
The complex pharmacological innervation presumably reflects the complexity of control of 
bladder function at multiple levels within the central and autonomic nervous systems.  
The bladder itself is innervated by muscarinic and nicotinic cholinergic inputs and 
adrenergic and noradrenergic inputs182. No specific morphological, pathological or biochemical 
alterations have been found to occur in the bladder in PD patients183. Most evidence for 
dopaminergic involvement in bladder function has arisen from experimental studies in animals. 
Unilateral lesions of the nigro-striatal pathway using 6-OHDA in the rat cause bladder hyper-
reflexia as does the administration of MPTP in non-human primate species184-187. Electrical 
stimulation of the substantia nigra and the direct injection of dopamine into the striatum can 
reverse these changes. Interestingly, D1R agonists improve bladder function whereas D2R 
agonists either have no effect or make it worse188. More recently, stem cell placement in the 
median forebrain bundle of 6-OHDA-lesioned rats was shown to ameliorate bladder 
dysfunction189. Together, this evidence suggests a centrally mediated mechanism underlying 
hyper-reflexia in PD. There has been little activity in developing novel treatments specifically 
aimed at bladder dysfunction in PD, although A2A receptor adenosine antagonists have been 
suggested as potentially effective in PD, based on action at a supraspinal site in 6-OHDA-
lesioned rats176. 
 
[H3] Gastrointestinal dysfunction. Dysfunction occurs along the entire length of the gastro-
intestinal tract in PD, and includes excessive salivation, dysphagia, impaired gastric emptying, 
constipation and impaired defecation190. Small intestinal bacterial overgrowth may complicate 
25–67% of cases with PD191. The cause of the gastrointestinal dysfunction is not well 
understood and may involve extrinsic and intrinsic pathological and biochemical changes. 
Multiple neurotransmitters and neuromodulators (for example, acetylcholine, 5-HT, dopamine, 
noradrenaline, vasoactive intestinal peptide (VIP) and nitric oxide) control bowel function and it 
is unlikely that there is a single pharmacological basis that is responsible for all the gastro-
intestinal symptomatology that is observed in PD. The dorsal motor nucleus of the vagus 
(DMNV) is important in autonomic control of the bowel, and pathological change in this area 
occurs early in the development of PD. This may explain why gastrointestinal disturbances such 
as constipation may also occur earlier than alterations in motor function192.  
Changes in the enteric nervous system (ENS) have also been reported in PD; for 
example, in one study, immunohistochemistry revealed a reduction in dopamine levels in the 
ENS, although there was no loss of tyrosine hydroxylase immunoreactivity, implying that no 
neurodegeneration had occured193. A further study failed to show any neuronal loss in the 
myenteric plexus along the length of the gastro-intestinal tract in control subjects, individuals 
with PD and cases of ILBD194. Also, no difference was observed between these groups in the 
relative abundance of tyrosine hydroxylase-, VIP- and nitric oxide-containing neurons. What is 
clear, however, is the presence of Lewy bodies (and/or α-synuclein inclusions and Lewy 
neurites) in PD at almost every level of the gastro-intestinal tract195. There is virtually no co-
localisation of α-synuclein with tyrosine hydroxylase, VIP or nitric oxide, suggesting that it is 
located in other neuronal types — perhaps cholinergic neurons.  
The presence of α-synuclein aggregations along the gastro-intestinal tract has been 
proposed as a diagnostic tool allowing early detection of the disease process prior to the onset 
of motor symptoms. Biopsy samples have been taken at multiple levels from the salivary glands 
to the rectum to determine the validity of this approach196-201. α-synuclein aggregates in colonic 
tissue so far appear to be the more predictive of pre-clinical PD. However, α-synuclein is 
abundantly expressed in all nerve plexuses of the ENS in normal individuals, and levels 
increase with age, so its pathological relevance needs to be carefully assessed before use as a 
predictive biomarker of PD202. 
Abnormalities of gastro-intestinal motility may be improved with both apomorphine and 
levodopa infusions81,,203. The gastro-intestinal effects of apomorphine are not prevented by the 
peripheral dopamine antagonist domperidone, suggesting that they have a central origin. There 
may also be a serotoninergic component to impaired motility and this is supported by enhanced 
gastrointestinal function following treatment with cisapride and related 5-HT4 receptor 
agonists176.  
Rodents treated with dopaminergic toxins or overexpressing wild-type or A53T mutant α-
synuclein can show slowed intestinal motility and constipation204-207. In mice overexpressing 
human wild-type α-synuclein, functional assessments demonstrated a reduction in faecal water 
content and faecal pellet output, and increased whole gut transit time, which is indicative of 
constipation208. Delayed gastric emptying was observed in 6-OHDA-lesioned rats and this may 
reflect the delayed emptying that is observed in PD that can affect levodopa absorption209. In 
unilateral 6-OHDA-lesioned rats, there was a marked loss of nitric oxide synthase-positive 
neurons and an increased number of VIP-positive cells in the myenteric plexus204. Moreover, in 
the colon of these animals, there was no change in choline acetyl transferase immunoreactivity 
but there was selective loss in D2R density. In the colon of MPTP-treated non-human primates, 
by contrast, there was increased number of nitric synthase immunoreactive neurons, a 
decrease in tyrosine hydroxylase immunoreactivity and no change in cholinergic- or VIP- 
immunoreactive populations210. The differences in the rat and primate findings may lie in the 
focal degeneration of nigro-striatal neurons that is produced by intra-nigral 6-OHDA 
administration as opposed to the systemic administration of MPTP that could potentially also 
destroy peripheral dopaminergic cells. However, these results seem to contrast with the effects 
in man and neither toxin would destroy neurons in the DMNV.  
 
[H3] Cardiovsacular features. The heart is innervated by sympathetic (noradrenergic and 
adrenergic) and parasympathetic (cholinergic) autonomic fibres that control heart rate and 
contractility. Cardiac autonomic dysfunction may occur in up to 80% of patients with PD211. This 
dysfunction encompasses orthostatic hypotension and labile hypertension. Orthostatic 
hypotension is a marker of sympathetic dysfunction and is common in PD with a reported 
frequency of 30–58%212. Twenty-four hour blood pressure monitoring showed that alterations in 
blood pressure profile and supine hypertension often occur in PD, usually in patients who 
develop orthostatic hypotension213. Nocturnal (supine) hypertension in PD has been shown to 
be associated with target organ damage as well as an increased risk for stroke and 
cardiovascular events214. 
Motor response fluctuations in PD may also affect cardiovascular function, and off 
periods have been shown to be associated with hypertension, a higher resting heart rate and a 
greater orthostatic fall of blood pressure215. A study of non-motor features in untreated PD and 
healthy controls reported that the former had a markedly raised heart rate, suggesting this may 
serve as a marker of early PD216. Postprandial hypotension has also been documented in PD, 
which appears to worsen the motor state in PD after a carbohydrate load and may explain the 
absence of on periods that are often seen after a meal217. A retrospective analysis of 
cardiovascular stress testing in asymptomatic individuals showed that during peak exercise, the 
maximum heart rate and the percentage of theoretical maximum heart rate were markedly lower 
in people that developed PD than in control subjects218.  
Despite the clinical evidence for altered cardiovascular function in PD, there has been 
relatively little investigation of this change in function in experimental models of the disorder. An 
impaired baroreflex response occurs in mice overexpressing human wild-type α-synuclein219. 
Moreover, mice expressing A53T mutant α-synuclein show aberrant autonomic control of the 
heart, which is characterised by elevated resting heart rate and an impaired cardiovascular 
stress response, associated with reduced parasympathetic activity220. Systemic MPTP treatment 
of mice can lead to decreased cardiac uptake of 125I-metaiodobenzylguanidine (MIBG), a 
physiological analogue of noradrenaline, decreased activity of cardiac noradrenaline transporter 
and reduced circulating and tissue levels of noradrenaline221-223. There may be recovery over 
time following toxin treatment and myocardial nerve fibres are preserved despite changes in 
cardiac contractility 224,225. By contrast, a single study of MPTP administration to non-human 
primates showed, if anything, an acute increase in 6-15F-fluorodopamine (15F-DA) on PET but 
no long term changes in 15F-DA imaging226. The differences in effects on cardiac innervation 
may be a reflection of the much higher doses of MPTP used to treat mice versus primates and 
also to its relative selectivity for dopaminergic neurons, although acute MPTP treatment can 
exert a reversible ‘reserpine’-like effect that depletes all monoamines227.  
The effects of MPTP on non-human primates is in marked contrast to the effects of 
peripheral 6-OHDA treatment of primates, which led to a marked reduction in 15F-DA uptake, as 
would be expected from its known toxicity to noradrenergic innervation in peripheral tissues226. 
Indeed, in a subsequent study, intravenous administration of 6-OHDA to monkeys caused an 
almost total loss of 11C-meta-hydroxyephedrine uptake, as judged by PET, followed by a partial 
progressive recovery but with decreased levels of circulating catecholamines228. This finding 
raises the issue of whether central dopamine loss has a role in peripheral cardiovascular 
change, which has been partially addressed in rats. Injection of 6-OHDA in to the medial 
forebrain bundle decreased the nocturnal heart rate in rats, whereas injection in to the ventral 
tegmental area altered circadian blood pressure regulation28,229. In a recent study, bilateral 
injection of 6-OHDA into rat substantia nigra lowered the mean arterial pressure, decreased 
heart rate and reduced sympathetic activity230. Overexpression of wild-type α-synuclein in mice 
caused increased heart rate variability whereas expression of A53T mutant α-synuclein did not 
induce cardiac autonomic abnormalities despite inducing profound ENS changes28. 
 
[H1] Perspectives 
Until relatively recently, PD has primarily been considered a motor disorder, with its dominant 
clinical features the result of dopaminergic neuron degeneration. Although dopamine cell loss 
clearly has a major role in PD symptomatology and has been the basis for the development of 
dopamine-replacement symptomatic therapies, this focus on motor deficits has relegated non-
motor problems to a secondary role. As a result, valuable insights on disease pathogenesis, 
clinical evolution and progression, and novel therapies have been missed or delayed. The 
emergence of non-motor abnormalities before motor deficits in PD has led to their use to help 
define an at-risk cohort of individuals (BOX 1). Probably the most useful of the prodromal non-
motor features that may help define a premotor phase are the loss of olfaction, the development 
of RBD, depression and constipation. However, before these features can be used to identify 
individuals at risk of PD, additional, more-specific clinical, genetic and/or biochemical markers 
will need to be identified.  
The pattern and sequence of the emergence of non-motor symptoms support the 
concept of a prion-like conformational templating spread of α-synuclein deposition from the gut 
through the autonomic plexi to the brain stem and beyond to the cortex.231,232nter-neuronal 
spread of α-synuclein has been confirmed in cell and animal models233-237. The observation that 
the injection of either the proteasomal inhibitor PSI (proteasomal inhibitor-1; N-
[(phenylmethoxy)carbonyl]-L-isoleucyl-L-α-glutamyl-tert-butyl ester-N-[(1S)-1-formyl-3-
methylbutyl]-L-alaninamide) into the gastric wall, or intragastric administration of the 
mitochondrial inhibitor rotenone may initiate α-synuclein release in the gut and its transmission 
to the dorsal motor nucleus of the medulla and substantia nigra of the mid-brain support two 
important concepts emerging in PD pathogenesis238,239. The first is that an intestinal trigger (for 
example, a toxin) may initiate α-synuclein release (and possibly oligomer formation) from 
autonomic nerves in the gut. The second is the potential for spread of α-synuclein pathology 
through connected neuronal pathways to the brain. The pattern of spread from the gut to brain 
may underlie the pre-motor features of autonomic gastro-intestinal dysfunction in PD; for 
example, constipation, cardiac denervation as shown by MIBG and the development of RBD. It 
has been suggested that the neurodegenerative process spreads from the olfactory bulb, the 
autonomic gut plexi, the intermediolateral nucleus of the spinal cord and the dorsal motor 
nucleus of the vagus in a caudorostral direction to the brain and also from the brainstem into the 
spinal cord (FIG. 4) 73,240. However, this pattern of spread may not apply to all PD patients and 
7–8% of patients have been reported with no α-synuclein pathology in the dorsal motor 
nucleus241,242.  
Thus, the focus on non-motor dysfunction in PD has informed and supported novel 
concepts of aetiology and pathogenesis. The early disturbance of olfaction, sleep and/or 
autonomic function implies neuronal dysfunction and is consistent with the sequence and 
pattern of the hypothesised spread of Lewy body α-synuclein pathology. These early features 
have been proposed as indicators of prodromal, pre-motor PD.  
[H1] Conclusion 
The increasing focus of research on non-motor aspects of PD has provided valuable insights 
into the diversity of the clinical, pathological and neurochemical features of this disorder. The 
symptoms and signs of non-motor symptoms and signs of PD are now the subject of validated 
clinical assessments that can detect their presence and follow their progression over time. The 
recognition that non-motor features may develop before motor signs is leading to their 
evaluation as possible biomarkers, although their detectionis likely to be most effective in 
conjunction with imaging and biochemical parameters. Importantly, attention is now being 
focussed on the treatment of non-motor features to improve patients’ quality of life. As non-
motor problems are a significant, if not even the predominant determinant of PD quality of life, it 
is essential that any intervention in PD pathogenesis to slow the disease targets not only 
dopaminergic signalling but also non-dopaminergic pathways. 
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Box 1 | Non-motor features as biomarkers for Parkinson disease  
Two areas of Parkinson disease (PD) research in non-motor features are of particular relevance 
to progress in this area: the development of biomarkers to identify pre-symptomatic PD243,244 
and modifying pathogenetic pathways that cause degeneration of dopaminergic and non-
dopaminergic neurotransmitter systems245. 
The diagnosis of PD remains dependent on the identification of motor signs that include 
bradykinesia and rigidity, with a unilateral resting tremor, and a subsequent good response to 
levodopa. However, it has been recognised that these diagnostic features may be preceded by 
non-motor symptoms and signs246, which include hyposmia, RBD, constipation and depression. 
Each of these symptoms may be present several years before the emergence of motor deficits. 
None of these symptoms are specific for PD, but the presence of combinations of these 
symptoms, and correlation with pre-clinical loss of dopamine observed by imaging, can improve 
sensitivity and specificity of the prediction for conversion from pre-symptomatic to symptomatic 
PD222,247. 
A putative biomarker that  changes in parallel to the progression of pathology and clinical 
features would be of particular value for testing treatments designed to slow the course of PD. 
The identification of genetic causes of PD, and the recognition that they also cause non-motor 
features248, have helped identify predisposed individuals to participate in longitudinal studies to 
track the development of prodromal, pre-clinical symptoms and signs. However, only the 
cohorts of individuals with PD-associated mutations in leucine-rich repeat serine/threonine-
protein kinase 2 (LRRK2) or glucocerebrosidase (GBA1) are of sufficient size to perform such 
studies. It also may be possible to undertake ’reverse genetics’ by metabolomic screening of 
defined population groups (for example, patients with PINK1 or PARK2 mutation-related PD) to 
identify a specific biochemical profile within this group, and then seek this same profile to define 
those among an idiopathic group that might have an underlying mitochondrial defect. This 
approach is being used in the GBA1 mutation population where non-motor features of 
prodromal PD have been found in asymptomatic mutation carriers249. Follow up of this cohort 
has shown progression of the non-motor as well as motor consequences of neurodegeneration 
evolving towards clinical PD250. It is hypothesised that those that convert to clinical PD will have 
exhibited a specific clinical and metabolic prodrome that may be used to identify those at risk of 
PD in the GBA1-mutation carrier population. These individuals may then be the most 
appropriate population for stratification for disease-modifying treatments that may include small 
molecule chaperones251,252.  
  
Figure 1 | Time courses of the onset of the motor and non-motor features of Parkinson 
disease. a | A schematic representation of the potential timeline by which the non-motor 
features of Parkinson disease (PD) may manifest. Non-motor symptoms may develop 
insidiously in the prodromal phase several years before onset of motor features. The duration of 
this prodromal phase is variable, as is the sequence of the appearance of the non-motor 
symptoms. Clinical features of motor dysfunction are required for the diagnosis of PD, and early 
disease may be associated with the emergence of additional non-motor symptoms. Non-motor 
problems continue to develop throughout the course of the disease with cognitive and 
autonomic features becoming common in the later stages. The sequence, timing and the 
development of the non-motor symptoms in PD can vary between patients. b |A graphic 
depiction of the rates of development and progression of the motor and non-motor features of 
PD, and the decline in dopaminergic neuronal function. The rate of decline in dopaminergic 
function (caused by the dysfunction and death of dopaminergic neurons) in PD may be variable 
(as represented by the blue shaded region) and depend on genetic and/or non-genetic 
influences on aetiology. It is estimated that motor features appear when approximately 50–60% 
of dopaminergic neurons have been lost (represented by the dark blue shaded area253. 
Diagnosis may be preceded by subtle emerging motor features not noticed by the patient. If left 
untreated, motor dysfunction progresses relatively rapidly after diagnosis. Symptomatic 
treatment with dopamine replacement drugs improves motor function and the progression rate 
declines as a ceiling effect of disability is reached. Non-motor features may begin with an earlier 
pre-motor prodrome, progress more slowly but accumulate greater disability. The majority of 
non-motor features are not related to dopaminergic cell loss and so are unaffected by dopamine 
replacement therapy. 
 
  
Figure 2 | Potential non-motor features in Parkinson disease.  The non-motor features of 
Parkinson disease reflect deficits in various functions of the CNS and autonomic nervous 
system.  Multi-system involvement develops to varying levels of severity and in a variable 
sequence in different patients. Although some non-motor impairments precede motor 
abnormalities (for example, cardiac, bowel and olfactory deficits), most develop over time with 
progression of the underlying disease. Cognitive dysfunction usually appears late in the course 
of PD, although visual hallucinations may appear earlier and are a risk factor for subsequent 
dementia. 
  
Figure 3 | Lewy bodies in Parkinson disease. a | Lewy bodies are intraneuronal 
intracytoplamic inclusions that are rich in α-synuclein. In the left-hand panel, a Lewy body is 
revealed by haematoxylin and eosin staining, whereas in the right-hand panel, this type of 
inclusion is revealed by α-synuclein immunohistochemistry.  Inclusions are also seen in axons 
and are referred to as Lewy neurites (not shown). The scale bar represents 10 μm. b | The 
Braak hypothesis states that Lewy bodies first appear in the CNS in the lower medulla and 
olfactory nerves, and spread from the medulla up the brain stem to the mid-brain where 
neurodegeneration first occurs in the dopaminergic neurons of the substantia nigra pars 
compacta (shaded areas affected first). Subsequently, there is involvement of frontal and then 
occipital cortices254. Panel a is courtesy of J. Holton. [We will add the permission information for 
panel b here.] 
Nature Reviews Neuroscience 16, 109–120 (2015) doi:10.1038/nrn3887 
  
Figure 4 | Schema representing the hypothesis of pathology spread via the intestine in 
Parkinson disease. The vagus nerve provides parasympathetic innervation to the intestine 
from the oesophagus to the colon via the oesophageal (1), coeliac (2) and hypogastric (3) plexi, 
which connect to the vagal nucleus in the medulla. It is hypothesised that factors that initiate α-
synuclein pathology enter the gut via the nose or mouth, and that a prion-like spread of α-
synuclein misfolding may generate a cascade of pathology from the gut plexi to medulla and 
beyond, as proposed by Braak and colleagues73. [Again, we will add the necessary permission 
line here.] 
  
Table 1 | Overview of the brain regions and neurotransmitters implicated in the nonmotor symptoms of 
Parkinson disease. 
Nonmotor symptom Implicated brain region Implicated neurotransmitter(s) 
Hyposmia Olfactory bulb and amygdala Substance P 
Impaired colour vision Retina Dopamine 
Hallucinations Occipital cortex Dopamine 
Pain Basal ganglia, locus ceruleus, 
taphe nucleus, amygdala and 
thalamus 
Dopamine, serotonin and 
noradrenaline 
Anxiety Basal ganglia Dopamine and noradrenaline 
Depression Limbic and cortical areas Dopamine and noradrenaline 
Early cognitive dysfunction Frontal cortex Dopamine 
Dementia Temporal, parietal and occipital 
lobes 
Acetylcholine 
Sleep disturbance Hypothalamus and reticular 
formation 
Hypocretin (orexin) and 
dopamine  
Bladder hyper-reflexia Basal ganglia Dopamine 
Correlations are simplified [Au: I still feel this wording is not very clear. If this line is to be retained, I 
suggest using: ‘The associations in the table are simplified…’] and readers are referred to the text for 
detail.  
  
GLOSSARY 
Bradykinesia  
Abnormal slowness of movement. 
Rigidity 
Stiffness and increased tone of muscles. 
Levodopa 
Orally active dopamine precursor.  
Wearing off periods 
Re-emergence of dopamine deficiency-related symptoms (for example, stiffness, slowness or 
tremor). 
Off periods 
Similar to ‘wearing off’ but more severe in terms of symptom severity 
On periods 
Periods of effective dopamine replacement with restored motor function 
Hyposmia 
Reduction in the ability to detect odours.  
Rotenone 
A mitochondrial complex I inhibitor and common pesticide. 
α-Synuclein 
Protein that aggregates and forms the major constituent of Lewy bodies in neurons. Mutations in 
the gene encoding α-synuclein and overexpression of this protein are causes of familial PD. 
Anosmia 
Loss of the sense of smell. 
Lewy bodies 
Abnormal aggregates of proteinaceous material within neuronal cell bodies the major 
constituent of which is α-synuclein. 
Lewy neurites 
Abnormal aggregates of proteinaceous material within axons the major constituent of which is α-
synuclein. 
Incidental Lewy body disease 
The presence on pathological examination of Lewy body deposition, but without symptoms of 
PD during life. 
1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP). 
A mitochondrial complex I inhibitor that can cause dopaminergic neuron death and induce 
parkinsonism in humans. 
Paraesthesia 
Positive sensory phenomena (for example, pins and needles). 
Parkin 
Parkin protein, involved in mitophagy 
Endogenous depression 
Depressive symptoms that are not associated with triggers such as bereavement. 
Sleep attacks 
Sudden onset of sleep. 
Akathisia 
Motor restlessness. 
Nocturia 
The need to pass urine during the night 
Micturition 
The process of passing urine. 
Detrusor 
A muscle that controls bladder function. 
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KEY POINTS 
Non-motor symptoms are common in Parkinson disease (PD) and can appear before motor 
features and progress in both severity and diversity as the disease evolves. 
 
Both dopaminergic and non-dopaminergic pathology underlie the non-motor features and this 
pathology involves the central and autonomic nervous systems. 
 
There is no accurate toxin-induced or genetic animal model of PD pathology and models for the 
study of non-motor features are limited. 
 
A combination of non-motor features with additional biochemical and/or imaging studies may 
provide a means to identify prodromal, pre-motor PD. 
 
There is accumulating evidence that α-synuclein pathology may spread along neuronal 
pathways and that this may originate in the gastrointestinal tract autonomic plexi. 
 
Therapies designed to slow the course of PD will need to address pathology in non-
dopaminergic neurons so as to influence non-motor as well as motor features of the disease. 
 
